Masimo Corporation Announces Study: SedLine® Brain Function Monitoring Reduces Pediatric Anesthesia Risks and Costs

Reuters
2025/06/10
Masimo Corporation Announces Study: SedLine® Brain Function Monitoring Reduces Pediatric Anesthesia Risks and Costs

Masimo Corporation has announced the findings of a new clinical trial, published in JAMA Pediatrics, demonstrating the advantages of its SedLine® Brain Function Monitoring technology in pediatric anesthesia. The study, conducted by Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University, involved children aged 1 to 6 years undergoing elective surgery. The results showed that EEG-guided anesthesia using SedLine significantly reduced the exposure to sevoflurane, a commonly used inhalation anesthetic, and lowered the incidence of pediatric anesthesia emergence delirium (PAED). Children monitored with SedLine regained consciousness 53% sooner and were discharged from the post-anesthesia care unit 48% sooner compared to those in the control group. These outcomes suggest improvements in safety, efficiency, and cost-effectiveness of pediatric anesthesia. The findings have been presented and are available for review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Masimo Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610391732) on June 10, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10